Position:
Global Head Clinical Development Equity
Company:
Novartis
Bio:
After a decade as an academic scientist, following a Ph.D. in Molecular Biology, Ambily moved to GSK Regulatory Affairs. Whilst leading GSK’s UK Brexit preparations for Regulatory Affairs across all of GSK’s Business Units, Ambily led a race and ethnicity Employee Resource Group at GSK, where she worked with the CEO, Chief Executive Team and Board members to implement global changes to ensure equity for ethnic minorities. In Nov 2021, she moved to Novartis, as Head of DEI for Global Drug Development (GDD) and in October 2022 became Global Head Clinical Development Equity. Her primary role is to drive clinical trial diversity, ensuring equitable access to trials especially for underserved communities globally. She is part of the Novartis DEI LT and a member of GDD ESG Council.
Externally, Ambily is the Deputy Chair of The Network of Networks, which brings together ERG leads from 130+ organisations to share best practices. Ambily serves on the Board of a not-for-profit ‘Micro:bit Educational Foundation’ (founded by the BBC) improving tech skills for under-represented populations. In 2021, Ambily was recognised with a Healthcare Businesswomen’s Association Rising Star award and appeared on Investing in Ethnicity and Empower Ethnic Minority Future Leader Lists. She is passionate about DEI and ensuring the next generation have equal access to opportunities.